Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;108(2):485-491.
doi: 10.1002/JLB.5MR0120-439R. Epub 2020 Mar 14.

Keratinocyte: A trigger or an executor of psoriasis?

Xinhui Ni  1 , Yuping Lai  1
Affiliations
Review

Keratinocyte: A trigger or an executor of psoriasis?

Xinhui Ni et al. J Leukoc Biol. 2020 Aug.

Abstract

Psoriasis is a common chronic inflammatory skin disease characterized by abnormal proliferation/differentiation of keratinocytes and excessive immune cell infiltration in the dermis and epidermis. Over the past 2 decades, immune cells have been considered as the main driver of psoriasis because the neutralizing antibodies targeting the IL-23/IL-17 axis that regulates cross-talk between dendritic cells and T cells achieve tremendous success in the treatment of psoriasis. However, whether keratinocyte would be a driver of psoriasis or just an executor in response to immune cells is still under debate. In this review, we focus on the recent advances in the identification of keratinocyte as a trigger of psoriasis, summarize on the role of keratinocytes in self-perpetuating loop to maintain inflammation in psoriasis, and then discuss the possible roles of keratinocytes in the relapse of psoriasis.

Keywords: cytokines/chemokines; inflammatory response; mantainence; onset; relapse.

PubMed Disclaimer

References

REFERENCES

    1. Heng MC, Kloss SG, Kuehn CS, et al. The sequence of events in psoriatic plaque formation after tape-stripping. Br J Dermatol. 1985;112:517-532.
    1. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol. 1981;76:359-362.
    1. Giguere V, Ong ES, Segui P, et al. Identification of a receptor for the morphogen retinoic acid. Nature. 1987;330:624-629.
    1. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555-561.
    1. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-447.

Publication types